Mats Jerkeman
141 – 150 of 176
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.
(
- Contribution to journal › Article
-
Mark
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
(
- Contribution to journal › Article
- 2009
-
Mark
Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
-
Mark
Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.
(
- Contribution to journal › Article
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
(
- Contribution to journal › Article
-
Mark
(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)
(
- Contribution to journal › Published meeting abstract
-
Mark
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
(
- Contribution to journal › Article
-
Mark
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.
(
- Contribution to journal › Article
- 2008
-
Mark
Nuclear expression of the Non-B Cell Lineage Sox11 Transcription Factor Identifies Mantle Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.
(
- Contribution to journal › Published meeting abstract